Severe insulin-requiring diabetes in a noradrenergic giant pheochromocytoma: a secretory-metabolic phenotype paradox.
- 1Department of Endocrinology, Diabetes and Nutrition, NOVO Hospital, Pontoise 95300, France.
- 2Faculty of Health Sciences, Federal University of Rondonópolis, Rondonópolis 78736-900, Brazil.
Abstract
Pheochromocytoma is a rare catecholamine-secreting neuroendocrine tumor associated with hypertension and dysglycemia in 20% to 40% of cases. Insulin-requiring diabetes has been reported in tumors with an adrenergic profile, owing to epinephrine-mediated inhibition of β-cell secretion. A 37-year-old man with a normal body mass index and an 18-year history of insulin-requiring diabetes and hypertension was found to have a right adrenal mass measuring 10.1 × 8.0 × 6.7 cm. Biochemical evaluation showed a noradrenergic profile, with urinary normetanephrine greater than 5000 μg/24 hours (SI: >26 400 nmol/day; reference range, 70-538 μg/24 hours [SI: 370-2841 nmol/day]) and normal urinary metanephrine. Right adrenalectomy and histopathology confirmed an intra-adrenal pheochromocytoma. After surgery, insulin was discontinued, and glycated hemoglobin remained below 6.1% (SI: 41-43 mmol/mol) without therapy. A preoperative insulin requirement of 0.83 units/kg/day, normal C-peptide, and negative glutamic acid decarboxylase antibodies supported a mixed and reversible mechanism involving catecholamine-induced insulin resistance and β-cell suppression. Severe postoperative hypoglycemia was attributed to reversal of catecholamine excess. This case challenges the association of severe diabetes with adrenergic pheochromocytomas and suggests that catecholamine burden and exposure duration may be more important determinants of metabolic severity than secretory profile alone, after prolonged exposure to high catecholamine concentrations.
Related
- Reprogramming pathological secretory phenotype of chondrocytes inhibits neurovascular invasion for osteoarthritis treatment.
- Machine learning–derived intracellular protein–based prognostic model reflecting a senescence-associated secretory phenotype-driven immunosuppressive microenvironment in lung adenocarcinoma
- Phenotypic heterogeneity in pediatric pituitary stalk interruption syndrome: greater disease burden in the metabolic-onset phenotype
- A latent metabolic dysfunction phenotype integrating insulin resistance and leptin is associated with disease severity in COPD
- MCT1 activity defines an aggressive metabolic phenotype and therapeutic target in non-small cell lung cancer
BibTeX
@article{viola2026severe,
title = {{Severe insulin-requiring diabetes in a noradrenergic giant pheochromocytoma: a secretory-metabolic phenotype paradox.}},
author = {Luiz F Viola and Asma Guedioura and Josiane Neves Coelho and Adriana Santi and Catherine Campinos},
journal = {JCEM case reports},
year = {2026},
month = oct,
doi = {10.1210/jcemcr/luag323},
url = {https://europepmc.org/article/MED/42923692},
note = {CC BY},
}
RIS
TY - JOUR
TI - Severe insulin-requiring diabetes in a noradrenergic giant pheochromocytoma: a secretory-metabolic phenotype paradox.
AU - Luiz F Viola
AU - Asma Guedioura
AU - Josiane Neves Coelho
AU - Adriana Santi
AU - Catherine Campinos
PY - 2026
DA - 2026/10/22
JO - JCEM case reports
DO - 10.1210/jcemcr/luag323
UR - https://europepmc.org/article/MED/42923692
AB - Pheochromocytoma is a rare catecholamine-secreting neuroendocrine tumor associated with hypertension and dysglycemia in 20% to 40% of cases. Insulin-requiring diabetes has been reported in tumors with an adrenergic profile, owing to epinephrine-mediated inhibition of β-cell secretion. A 37-year-old man with a normal body mass index and an 18-year history of insulin-requiring diabetes and hypertension was found to have a right adrenal mass measuring 10.1 × 8.0 × 6.7 cm. Biochemical evaluation showed a noradrenergic profile, with urinary normetanephrine greater than 5000 μg/24 hours (SI: >26 400 nmol/day; reference range, 70-538 μg/24 hours [SI: 370-2841 nmol/day]) and normal urinary metanephrine. Right adrenalectomy and histopathology confirmed an intra-adrenal pheochromocytoma. After surgery, insulin was discontinued, and glycated hemoglobin remained below 6.1% (SI: 41-43 mmol/mol) without therapy. A preoperative insulin requirement of 0.83 units/kg/day, normal C-peptide, and negative glutamic acid decarboxylase antibodies supported a mixed and reversible mechanism involving catecholamine-induced insulin resistance and β-cell suppression. Severe postoperative hypoglycemia was attributed to reversal of catecholamine excess. This case challenges the association of severe diabetes with adrenergic pheochromocytomas and suggests that catecholamine burden and exposure duration may be more important determinants of metabolic severity than secretory profile alone, after prolonged exposure to high catecholamine concentrations.
SN - 2755-1520
ER -